Table 3.
Univariate and multivariate cox regression analyses for overall survival in patients with gastric cancer.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Primary cohort | ||||
| Sex: male vs. female | 1.00 (0.77–1.29) | 0.976 | ||
| Age: >60 vs. ≤60 | 1.23 (0.94–1.61) | 0.136 | ||
| Tumor location | 0.004* | 0.087 | ||
| Middle vs. upper | 0.73 (0.52–1.02) | 0.063 | 0.80 (0.56–1.13) | 0.201 |
| Lower vs. upper | 0.57 (0.40–0.79) | 0.001* | 0.66 (0.46–0.96) | 0.028* |
| Grade: poorly vs. well | 2.20 (1.71–2.83) | <0.001* | 1.42 (1.07–1.87) | 0.014* |
| Lauren type | 0.843 | |||
| Intestinal vs. diffuse | 1.05 (0.74–1.49) | 0.797 | ||
| Mixed vs. diffuse | 0.97 (0.67–1.39) | 0.853 | ||
| Tumor size: >5 vs. ≤5 | 2.04 (1.57–2.67) | <0.001* | 1.26 (0.94–1.70) | 0.127 |
| Lymphovascular: yes vs. no | 1.17 (0.89–1.54) | 0.256 | ||
| Perineural: yes vs. no | 1.74 (1.36–2.23) | <0.001* | 1.18 (0.89–1.56) | 0.247 |
| TNM stage | <0.001* | <0.001* | ||
| II vs. I | 2.32 (1.45–3.72) | <0.001* | 1.90 (1.17–3.07) | 0.009* |
| III vs. I | 6.17 (4.00–9.48) | <0.001* | 3.89 (2.47–6.14) | <0.001* |
| Chemotherapy: Yes vs. no | 1.15 (0.90–1.48) | 0.282 | ||
| SIRI: >0.85 vs. ≤0.85 | 2.06 (1.60–2.66) | <0.001* | 1.47 (1.11–1.94) | 0.006* |
| NLR: >1.32 vs. ≤1.32 | 1.69 (1.31–2.16) | <0.001* | 1.23 (0.90–1.71) | 0.196 |
| PLR: >128 vs. ≤128 | 1.83 (1.39–2.42) | <0.001* | 1.19 (0.88–1.59) | 0.256 |
| MLR: >0.24 vs. ≤0.24 | 1.86 (1.45–2.39) | <0.001* | 1.27 (0.98–1.66) | 0.073 |
| Dynamic change in SIRI | <0.001* | <0.001* | ||
| SIRI no change vs. decrease>50% | 2.33 (1.57–3.47) | <0.001* | 1.90 (1.27–2.86) | 0.002* |
| increase>50% vs. decrease>50% | 4.52 (2.89–7.05) | <0.001* | 4.01 (2.55–6.30) | <0.001* |
| Validation cohort | ||||
| Sex: male vs. female | 0.98 (0.56–1.69) | 0.932 | ||
| Age: >60 vs. ≤60 | 1.21 (0.94–1.57) | 0.141 | ||
| Tumor location | 0.833 | |||
| Middle vs. upper | 0.78 (0.35–1.75) | 0.547 | ||
| Lower vs. upper | 0.80 (0.34–1.88) | 0.614 | ||
| Grade: poorly vs. well | 1.27 (0.99–1.61) | 0.051 | ||
| Lauren type | 0.795 | |||
| Intestinal vs. diffuse | 1.21 (0.62–2.37) | 0.574 | ||
| Mixed vs. diffuse | 1.26 (0.64–2.49) | 0.507 | ||
| Tumor size: >5 vs. ≤5 | 2.07 (1.21–3.55) | 0.008* | 1.27 (0.56–2.89) | 0.570 |
| Lymphovascular: yes vs. no | 1.43 (0.86–2.36) | 0.168 | ||
| Perineural: yes vs. no | 1.85 (1.35–2.55) | <0.001* | 1.63 (0.71–3.74) | 0.250 |
| TNM stage | <0.001* | <0.001* | ||
| II vs. I | 2.55 (1.26–5.19) | 0.010* | 1.99 (0.93–4.25) | 0.075 |
| III vs. I | 6.02 (2.87–12.63) | <0.001* | 4.95 (2.14–11.47) | <0.001* |
| Chemotherapy: yes vs. no | 1.42 (0.88–2.31) | 0.154 | ||
| SIRI: >0.85 vs. ≤0.85 | 2.49 (1.54–4.01) | <0.001* | 2.21 (1.18–4.15) | 0.001* |
| NLR: >1.32 vs. ≤1.32 | 2.49 (1.36–4.58) | 0.003* | 1.80 (0.91–3.56) | 0.154 |
| PLR: >128 vs. ≤128 | 2.15 (1.32–3.49) | 0.002* | 1.56 (0.87–2.80) | 0.132 |
| MLR: >0.24 vs. ≤0.24 | 1.94 (1.20–3.13) | 0.007* | 1.62 (0.98–2.69) | 0.060 |
| Dynamic change in SIRI | <0.001* | <0.001* | ||
| SIRI no change vs. decrease>50% | 2.70 (1.23–5.89) | 0.013* | 2.18 (0.96–4.95) | 0.064 |
| Increase>50% vs. decrease>50% | 6.54 (3.14–13.63) | <0.001* | 4.93 (2.28–10.67) | <0.001* |
*represents statistical significance.